Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
J Gastrointest Surg. 2014 Jan;18(1):106-11; discussion 112. doi: 10.1007/s11605-013-2334-y. Epub 2013 Sep 10.
Laparoscopic Heller-Dor surgery is the current treatment of choice for patients with esophageal achalasia, but elderly patients are generally referred for less invasive treatments (pneumatic dilations or botulinum toxin injections).
To assess the effect of age on the surgical outcome of patients receiving laparoscopic Heller-Dor as primary treatment.
Demographic and clinical findings were prospectively collected on patients undergoing laparoscopic Heller-Dor from 1992 to 2012. Patients were classified in three age brackets: group A (≤45 years), group B (45-70), and group C (≥70). Treatment was defined as a failure if the postoperative symptom score was >10th percentile of the preoperative score (i.e., >8). We consecutively performed the Heller-Dor in 571 achalasia patients, 305 (53.4 %) in group A, 226 (39.6 %) in group B, and 40 (7 %) in group C.
The mortality was nil; the conversion and morbidity rates were both 1.1 %. Group C patients had higher preoperative symptom scores (p = 0.02), while the symptom duration was similar in all three groups. Mucosal tears occurred in 17 patients (3 %): 6 (2 %) in group A, 8 (3.5 %) in group B, and 3 (7.5 %) in group C (p = 0.09). The postoperative hospital stay was slightly longer for group C (p = 0.06).
The treatment failure rate was quite similar: 31 failures in group A (10.1 %), 19 in group B (8.4 %), and 3 in group C (7.5 %; p = 0.80). These failures were seen more in manometric pattern III (22.2 %, p = 0.002). Laparoscopic Heller-Dor can be used as the first therapeutic approach to achalasia even in elderly patients with an acceptable surgical risk.
腹腔镜 Heller-Dor 手术是目前治疗食管失弛缓症的首选方法,但老年患者通常会选择接受侵袭性较小的治疗方法(气囊扩张或肉毒毒素注射)。
评估年龄对接受腹腔镜 Heller-Dor 作为主要治疗的患者手术结果的影响。
前瞻性收集 1992 年至 2012 年期间接受腹腔镜 Heller-Dor 手术的患者的人口统计学和临床资料。患者分为三组:A 组(≤45 岁)、B 组(45-70 岁)和 C 组(≥70 岁)。如果术后症状评分超过术前评分的第 10 百分位数(即>8),则将治疗定义为失败。我们连续对 571 例贲门失弛缓症患者进行了 Heller-Dor 手术,其中 A 组 305 例(53.4%),B 组 226 例(39.6%),C 组 40 例(7%)。
无死亡病例;转换率和发病率均为 1.1%。C 组患者术前症状评分较高(p=0.02),但三组患者的症状持续时间相似。17 例患者(3%)发生黏膜撕裂:A 组 6 例(2%),B 组 8 例(3.5%),C 组 3 例(7.5%)(p=0.09)。C 组患者术后住院时间略长(p=0.06)。
治疗失败率相当相似:A 组 31 例(10.1%),B 组 19 例(8.4%),C 组 3 例(7.5%)(p=0.80)。这些失败在压力模式 III 中更为常见(22.2%,p=0.002)。即使对于手术风险可接受的老年患者,腹腔镜 Heller-Dor 也可以作为贲门失弛缓症的首选治疗方法。